APP Dosage and Extracellular Domain Variants Drive Distinct Defects in Neurogenesis modeled in Down Syndrome iPS cells
Melvys ValledoriD, Kelly Smith, Jeanne Bentley LawrenceiD, Lucas Javier SosaiD
Abstract
The amyloid precursor protein (APP) is heavily studied as the source of amyloid beta in Alzheimers disease (AD), however, the complex functions of APP remain poorly understood, as does the impact of APP dosage on neurodevelopment. Here we study APP specifically in the context of Trisomy 21. In an effort to reduce APP dosage in trisomy 21 iPSCs, we generated trisomic isogenic lines which vary in APP dosage, including a full APP knock-out line, as well as lines carrying mutations of the APP extracellular domain. We used a panel of these lines to study potential impacts of APP dosage or structure on two distinct steps of neurogenesis in trisomic cells: 1) terminal differentiation of human neuro-progenitor cells (NPC) to post-mitotic neurons and 2) neuron structure as reflected in neurite outgrowth. Complete loss of APP causes marked defects in each of these two distinct steps, reducing both the terminal differentiation of NPCs to neurons, and proper neurite development for extended neuron structure. Hence, APP is necessary for both aspects of normal neurogenesis. Further analyses of the null and other mutant lines indicate that APP likely impacts these two distinct steps by two different mechanisms. Collective results suggest that the reduced terminal differentiation of NPCs reflects an effect of APP dosage, whereas the defects in neurite extension are due to structural mutation of the APP extracellular domain. Absence of APP or reduced (monosomic) APP dosage prolonged the cycling of trisomic NPCs, which is known to be regulated by Notch signaling. APP and Notch are the main targets of gamma-secretase cleavage, hence we hypothesized that APP dosage may impact neurogenesis indirectly, potentially via effects on Notch signaling. To test this, we treated NPCs with Compound E which inhibits gamma-secretase (and Notch signaling); results show this restored levels of neurogenesis in APP depleted lines, supporting an indirect effect of APP dosage. In contrast, results indicate that disruption of APP extracellular domain integrity impacts neurite extension via a more direct role of APP in neuron structural maturation. This study describes a resource of well-characterized APP mutant isogenic DS iPSC lines, implicates a dynamic interplay between APP dosage and Notch signaling, and raises new questions about the impact of APP dosage in orchestrating neural progenitor fate decisions during human brain development, specifically in the context of trisomy 21.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Amyloid precursor protein dosage normalization rescues neurogenesis and Alzheimer's Disease phenotypes associated with Down Syndrome
Deepika Patel, Karen Rakowiecki, Orly Lazarov·Medical Research ArchivesPeer-reviewed·Jan 1, 2026
- Amyloid precursor protein mediates deficits in corticogenesis in Down syndrome cortical organoids
Karen Rakowiecki, Deepika Patel, … Orly Lazarov·bioRxiv·Jul 26, 2025
- Human neurons lacking amyloid precursor protein exhibit cholesterol-associated developmental and presynaptic deficits
Haylee Mesa, Elaine Y. Zhang, … Qi Zhang·Journal of Cellular PhysiologyPeer-reviewed·Mar 26, 2023
- A role for APP in the development of astrocyte morphological complexity
Margaux Saint‐Martin, Yukiko Goda·bioRxiv·Sep 9, 2023
- The temporal balance between self-renewal and differentiation of human neural stem cells requires the Amyloid Precursor Protein
Khadijeh Shabani, Julien Pigeon, … Bassem A. Hassan·Science AdvancesPeer-reviewed·Jun 16, 2023
- APP overexpression delays synaptic development and alters neuronal network properties
Fulin Ma, Himanshu Akolkar, … Karl Herrup·bioRxiv·Mar 12, 2025